Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Department of Hepatology, Yangon Specialty Hospital, Yangon, Myanmar/Burma.
Dig Dis. 2022;40(6):745-753. doi: 10.1159/000521768. Epub 2022 Jan 5.
Chronic hepatitis B (CHB) patients with metabolic syndrome (MetS) may present increased risk of liver-related outcomes (LROs), but prior studies were limited by small sample size and/or conflicting results. Using a systematic review and meta-analytic approach, we aimed to determine the association between MetS and LROs in CHB.
Two researchers independently screened studies from the PubMed, Embase, Web of Science, and Cochrane Library databases from inception to January 21, 2020, and extracted the data. Estimates were pooled using a random-effects model.
We screened 2,228 articles and included 10 eligible studies (18,360 CHB patients, 2,557 with MetS). MetS was significantly associated with LROs overall (odds ratio = 2.45, 95% confidence interval = 1.39-4.32) but not the individual LRO components but subgroup analyses were limited by small study numbers.
DISCUSSION/CONCLUSION: MetS is associated with almost 3-folds higher risk of LROs in CHB and should be considered in management decisions. However, additional studies are needed.
患有代谢综合征（MetS）的慢性乙型肝炎（CHB）患者可能存在更高的肝脏相关结局（LROs）风险，但先前的研究受到样本量小和/或结果冲突的限制。我们采用系统评价和荟萃分析的方法，旨在确定 MetS 与 CHB 患者 LROs 之间的关联。
两名研究人员独立筛选了从建库至 2020 年 1 月 21 日发表在 PubMed、Embase、Web of Science 和 Cochrane Library 数据库中的研究，并提取数据。使用随机效应模型汇总估计值。
我们筛选了 2228 篇文章，纳入了 10 项符合条件的研究（18360 例 CHB 患者，2557 例患有 MetS）。MetS 与 LROs 总体相关（比值比=2.45，95%置信区间=1.39-4.32），但与单个 LRO 成分无关，但亚组分析受到研究数量较少的限制。
讨论/结论：MetS 与 CHB 患者 LROs 的风险增加近 3 倍相关，在管理决策中应考虑到这一点。但是，还需要更多的研究。
